{"id":"NCT00909844","sponsor":"Ipsen","briefTitle":"Effects of Triptorelin Pamoate in Children With Precocious Puberty - Follow up Study","officialTitle":"Follow-up of the Phase III, Multicentre, Non Comparative, One Single Group, Open Study to Assess the Long-term Efficacy and Tolerability of Pamoate of Triptorelin 11.25 mg in Children With Precocious Puberty","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-04","primaryCompletion":"2015-04","completion":"2016-01","firstPosted":"2009-05-29","resultsPosted":"2017-05-01","lastUpdate":"2019-01-15"},"enrollment":35,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Precocious Puberty"],"interventions":[{"type":"DRUG","name":"Triptorelin (I.N.N.)","otherNames":[]}],"arms":[{"label":"Triptorelin","type":"EXPERIMENTAL"}],"summary":"The purpose of the protocol is to assess the efficacy of triptorelin 11.25 mg with respect to the proportion of children who maintain a regression or stabilisation of sexual maturity until the end of the study.","primaryOutcome":{"measure":"Percentage of Children With a Stabilisation or Regression of Tanner Pubertal Stage at the End of the Study (Final Visit), Compared to Pretreatment (Month -6) and Baseline (Month 0)","timeFrame":"Months 12, 24, 36, 48 and Final Visit (if applicable; up to 63 months)","effectByArm":[{"arm":"Triptorelin Pamoate 11.25 mg","deltaMin":61.8,"sd":null}],"pValues":[]},"eligibility":{"minAge":null,"sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":2},"locations":{"siteCount":10,"countries":["France"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":35},"commonTop":["Abdominal pain","Injection site pain","Headache","Hot flush","Vomiting"]}}